EMBRYOGENESIS, a leading name in fertility diagnostics, is at the forefront of advanced artificial reproductive technology. Specializing in thorough infertility diagnostics and effective fertility treatments, EMBRYOGENESIS is committed to supporting couples in their journey toward parenthood. Their highly skilled professionals—fertility scientists, sonographers, embryologists, nurses, and counselors—work seamlessly together to provide exceptional care in a compassionate, nurturing environment. EMBRYOGENESIS takes pride in harnessing cutting-edge technological advancements to address infertility challenges efficiently, ensuring the highest treatment standards for couples striving to build their families.
In an exclusive conversation with The Interview World during NBHC 2024, Dr. Pulakes Purkait, Founder and Director of EMBRYOGENESIS, elaborates on the innovative products his company has developed to tackle infertility challenges. He also shares insights on the affordability of diagnostic technology and the widespread use of these kits across IVF clinics. Additionally, Dr. Purkait highlights his ambitious expansion and new product development plans. Here are the key highlights from his conversation.
Q: Could you elaborate on the innovative approaches EMBRYOGENESIS is using to address the challenges associated with infertility?
A: EMBRYOGENESIS is a specialized center for infertility diagnostics and research. We focus on advanced endometrial testing, an area that was notably underdeveloped in India. Previously, such tests were only available abroad, often through international partners. We have successfully developed comprehensive endometrial receptivity and function assessments in India, enabling us to identify the root causes of implantation and IVF failures.
This test allows us to pinpoint the specific issue and offer tailored treatment options for each patient. The results from our personalized treatments have been exceptional, supported by numerous case studies. Our success rate exceeds 90 percent.
With precise diagnoses and targeted treatment plans, patients experience significant benefits. IVF centers also see remarkable success, enhancing their outcomes and overall patient satisfaction.
Q: Do you offer healthcare services, or do you provide diagnostic products?
A: Our service involves sending a team equipped with our indigenously developed sample kit to IVF centers, gynecologists, and doctors. The kit facilitates the collection of an endometrial biopsy on a specific day, which we emphasize as critical for accurate testing.
The timing is essential because we capture the sample during the window of implantation—the precise day when an embryo attaches to the uterus, or endometrium. This is when the necessary molecules for a successful pregnancy are present. By analyzing this specific day, we can provide the most reliable insights.
We conduct the test using our patented Endometrial Receptivity and Function Assay (ERFA), which we refer to as the “soil test.” This innovative approach enables precise assessment of endometrial conditions to optimize fertility outcomes.
Q: How affordable is the technology you have developed for potential users?
A: Our test is highly affordable, especially when compared to the high costs of infertility treatments. While treatments can be expensive, our test is priced between Rs. 15,000 and Rs. 20,000. To put this in perspective, a single marker test in the UK can cost around $500. In contrast, we utilize over 10 markers combined, making our test both comprehensive and cost-effective. This level of affordability ensures that almost anyone can access this essential diagnostic service.
Q: How many IVF centers are currently using your kits?
A: We maintain selective partnerships with IVF centers that are already familiar with me and actively use our kits. Approximately 8 to 10 IVF centers incorporate our kits into their practices.
Q: Do you have plans to expand your services across India?
A: We are not only focused on expanding across India but are also making significant strides to grow globally. Moreover, we have initiated discussions with IVF clinics in the Netherlands, where several scientists have shown interest in our work. Additionally, we are in the early stages of conversations with IVF centers in the UK and the USA. Our efforts are already yielding results, as three clinics have reached us directly. With this momentum, we plan to launch our services internationally by next year.
Q: What other innovations are you planning to introduce in infertility treatment?
A: We are proud to be the first in India to develop this product. Additionally, we have already created another groundbreaking product, we patented just last month. This new test addresses pregnancy loss by identifying its root causes. It is essential to understand that implantation failure and pregnancy loss are distinct issues.
Implantation failure refers to the inability to become pregnant, while pregnancy loss occurs after conception. Our innovative test will precisely determine the cause of pregnancy loss, providing crucial insights. Beyond that, we are also advancing personalized medicine. While we do not prescribe personalized treatments directly, we empower doctors by offering tailored options to support patient care.
We focus on supporting IVF centers and doctors—not treating patients ourselves. Furthermore, we aim to enhance their ability to provide effective, personalized treatment strategies. Additionally, I hold a patented therapeutic solution designed to protect the baby during pregnancy, adding further value to the field of reproductive health.
